To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

SI-BONE (NasdaqGM:SIBN) Q3 2025 Earnings Call November 10, 2025 04:30 PM ET Company ParticipantsAnshul Maheshwari - CFOSaqib Iqbal - VP of Financial Planning and Analysis and Investor RelationsPatrick Wood - Managing DirectorCaitlin Roberts - Director of MedTech Equity ResearchLaura Francis - CEOConference Call ParticipantsNone - AnalystMatthew O'Brien - Senior Research AnalystNone - AnalystDavid Saxon - Equity Research AnalystRoss Osborn - Director and Lead Research AnalystYoung Li - SVP and Equity Researc ...

SI-BONE (NasdaqGM:SIBN) Q3 2025 Earnings Call November 10, 2025 04:30 PM ET Speaker1Good afternoon, and welcome to SI-BONE's Third Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. We will be participating in a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for repurposes. I'll now turn the call over to Saqib Iqbal, Vice President, FP&A Investor Relations at SI-BONE, for a few introductory comments. Please ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38701 SI-BONE, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdicti ...

The statements in this presentation regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement fo ...

Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Recent Operational Highlights (any comparisons are to the prior year period) SANTA CLARA, Calif. November 10, 2025 - SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2025. "The robust proce ...

Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.7 million, representing growth of 20.6% U.S. revenue of $46.4 million, representing growth of 21.2%Gross margin of 79.8%, representing an improvement of 75 basis pointsNet loss of $4.6 million, representing an improvement of 30.6% Positive adjusted EBITDA of $2.3 million ...

Core Insights - SI-BONE, Inc. will report its financial results for Q3 2025 on November 10, 2025, after market close [1] - A conference call will be held at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results [1] Company Overview - SI-BONE is a global leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,600 physicians in performing nearly 130,000 procedures, backed by over 175 peer-reviewed publications, including four randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]

Core Points - SI-Bone, Inc. experienced a data breach on or about October 1, 2025, which has led to an investigation into data privacy claims [1][3] - The breach may have exposed sensitive personal information, including names, Social Security numbers, driver's license numbers, addresses, medical information, and health insurance information [3] - Edelson Lechtzin LLP is investigating a potential class action lawsuit for individuals whose sensitive personal data may have been compromised [4] Company Overview - SI-Bone, Inc. is based in Santa Clara, California, and specializes in developing minimally invasive devices for treating sacropelvic conditions, particularly SI joint pain [2] Legal Context - Edelson Lechtzin LLP is a national class action law firm that focuses on various litigation areas, including data breaches, securities fraud, antitrust violations, and consumer fraud [5]

Group 1 - The company has evolved from focusing solely on the sacropelvic joint space to becoming a broader platform in the medical industry [1][2] - The company was established with a specific focus on the sacroiliac (SI) joint, which is the largest joint in the human body and previously lacked a surgical solution [2][3] - The CEO has been with the company for over 10 years, starting as CFO in 2015, indicating a strong leadership continuity [2]